Literature DB >> 6496365

Effect of propafenone on left ventricular ejection fraction.

B J Baker, H Dinh, D Kroskey, N D de Soyza, M L Murphy, J A Franciosa.   

Abstract

The effects of orally administered propafenone on ejection fraction (EF) determined by radionuclide angiography were studied in 2 groups of patients receiving different dosing regimens. Fourteen group A patients had no clinical evidence of left ventricular (LV) dysfunction and were not receiving digoxin therapy. In this group a mean daily dosage of 879 mg resulted in a decrease in resting LVEF from 52 +/- 9% to 48 +/- 11% (p less than 0.05). Eight group B patients had clinical radionuclide evidence of LV dysfunction and were receiving digoxin therapy. In this group, a daily dosage of propafenone of 600 mg/day resulted in no significant change in LVEF. No clinically significant effects on cardiac compensation were evident in either group. These data suggest a negative inotropic effect that is either related to propafenone dosage or at least partially attenuated by digoxin therapy. Further studies are necessary to define precisely the effects of propafenone on LV function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6496365     DOI: 10.1016/s0002-9149(84)80280-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Comparative hemodynamics of antiarrhythmic drugs.

Authors:  M Sami
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 2.  Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

3.  Syncope, widened QRS interval, and left ventricular systolic depression: coincident with propafenone therapy for atrial fibrillation.

Authors:  Rodney A Samaan; Hezekiah O Sobamowo; Frank Tamburrino; Richard Grodman; Nidal Isber
Journal:  Tex Heart Inst J       Date:  2010

4.  Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the CAST study.

Authors:  A Bayés de Luna; J Guindo; J Borja; M Roman; C Madoery
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 5.  New antiarrhythmic drugs in pediatric use: propafenone.

Authors:  T Paul; J Janousek
Journal:  Pediatr Cardiol       Date:  1994 Jul-Aug       Impact factor: 1.655

6.  Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).

Authors:  J Thormann; W Kramer; P Kremer; M Schlepper
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

7.  Anti-arrhythmic medications increase non-cardiac mortality - A meta-analysis of randomized control trials.

Authors:  Bhavi Pandya; Jonathan Spagnola; Azfar Sheikh; Boutros Karam; Viswajit Reddy Anugu; Asif Khan; James Lafferty; David Kenigsberg; Marcin Kowalski
Journal:  J Arrhythm       Date:  2016-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.